

**Amendments to the Specification:**

On page 1, replace paragraph [0001] with the following replacement paragraph:

**[0001]** This application claims the benefit of U.S. Provisional Application No. 60/552,279, filed March 10, 2004, and is a continuation-in-part of U.S. Application No. 09/910,406, filed July 19, 2001, pending, which claims the benefit of U.S. Provisional Application No. 60/219,128, filed July 19, 2000. This application also claims the benefit of Japanese Application No. 317160 filed October 17, 2000, now pending. These priority documents are incorporated herein by reference in their entirety.

On page 7, replace paragraph [0036] with the following replacement paragraph:

**[0036]** Figs. 8A-8D8E show the IL-10 (diamonds), IFN- $\gamma$  (squares), and IL-12 (triangles) serum levels, in pg/mL, for the six patients treated as described with respect to Figs. 7A-7B.

On page 24, replace paragraph [0099] with the following replacement paragraph:

**[0099]** Figs. 8A-8D8E show the IL-10 (diamonds), IFN- $\gamma$  (squares), and IL-12 (triangles) serum levels, in pg/mL, for the six patients in this study (Example 3). The actual IL-12 concentrations are 10 times the value shown in Figs. 8A-8D8E (actual values were divided by 10 to show all data on a single graph).

On page 25, replace paragraph [0104] with the following replacement paragraph:

**[0104]** ~~Fig. 8E shows the data for patient no. 405.~~ Patient No. 405 in this study had ~~This patient had an~~ initial IL-10 blood concentration of 34.9 pg/mL and an initial IL-12 blood concentration of 976 pg/mL (IL-10/IL-12 ratio 0.036; data not shown). Administration of IFN $\tau$  at a dosage of  $1.5 \times 10^9$  U per day was effective to increase the IL-10/IL-12 ratio to 0.058 at Day 71 of the treatment period, a 60% increase. The IL-10

blood concentration increased 20% from the initial pre-treatment level to the level at Day 71.

On page 42, replace paragraph [0160] with the following replacement paragraph:

**[0160]** Blood samples were taken at defined intervals over the 113 day test period. The samples were analyzed for IL-10, IL-12, and IFN- $\gamma$  levels in the serum using commercially available ELISA kits (Genzyme, Cambridge, Mass). The results are shown in Fig. 7A (IL-10), Fig. 7B (IFN- $\gamma$ ), and in Figs. 8A-8D8E (IL-10, IL-12, and IFN- $\gamma$ ) for each of the five patients.